We sit down with you and build your perfect lead list. Book a call with founders.

Halo-Bio RNAi Therapeutics Analysis

What is Halo-Bio RNAi Therapeutics?

Patented multivalent RNAi platform for multi-gene suppression and viral treatment

HQ Country
Seattle, United States
Employees
1-10
Founded
2008
HQ State/Province
Washington
HQ Full Address
Seattle, Washington, United States

Product Features & Capabilities

  • Multivalent RNAi trigger (MV-RNA) for multi-gene suppression
  • Self-forming RNA core (40 nm spheres) with targeted gene silencing
  • Programmable particle shells using aptamer-driven proteins for tissue-specific delivery
  • AmpliVIR RNA for SARS-2 self-inactivation
  • RNA nanoparticle formulations for intracellular delivery

Other Considerations

Pivoting research toward SARS-2 treatment with AmpliVIR RNA; Patented multivalent RNAi platform; Focus on programmable nanoparticle delivery; Early-stage development in RNA delivery and biopharmaceuticals; Research collaboration opportunities with scientists and institutions

Find more companies like Halo-Bio RNAi Therapeutics

VC-backed University Spinouts